This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Patients who require follow up in secondary care

Authoring team

Regular follow up in secondary care is recommended in patients:

  • all children
  • chronic colonization with P aeruginosa, opportunist mycobacteria or methicillin-resistant S aureus
  • worsening bronchiectasis with declining lung function
  • 3 or more exacerbations per year
  • who are on oral or nebulised prophylactic antibiotic therapy
  • with concomitant conditions such as rheumatoid arthritis, immune deficiency, inflammatory bowel disease, primary ciliary dyskinesia (PCD) or allergic bronchopulmonary aspergillosis (ABPA)
  • with advanced disease and those who are considered for transplantation.

Reference:

  1. Hill AT, Sullivan AL, Chalmers JD, et al British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respiratory Research 2018;5:e000348. doi: 10.1136/bmjresp-2018-000348
  2. Pasteur MC et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65 Suppl 1:i1-58

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.